secwatch.observer — SEC 8-K summary
======================================

Issuer:     AN2 Therapeutics, Inc. (ANTX)
CIK:        0001880438
Form:       8-K
Filed at:   2026-06-04T20:15:49+00:00
Accession:  0001193125-26-257430
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AN2 Therapeutics reports 100% parasite elimination in NHP study; Phase 2 for Chagas planned late 2026
--------------------------------------------------------------------------------

- 28-day AN2-502998 treatment in NHPs with chronic T. cruzi infection achieved 100% parasite elimination at human-target exposures, durable for 4 months post-treatment.
- Phase 1 FIH study (NCT07024589) in healthy volunteers showed favorable safety, no dose-limiting toxicities, and PK exposures at NHP efficacy thresholds.
- Chagas disease affects ~300k in U.S. and ~10M globally; no FDA-approved treatments for adults with chronic disease.
- Company plans to initiate Phase 2 proof-of-concept study late 2026; AN2-502998 eligible for FDA Tropical Disease Priority Review Voucher if approved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1880438/000119312526257430/0001193125-26-257430-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1880438/000119312526257430/d247428d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-257430

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer